Which phase(s) of the cardiac action potential does digoxin affect?

Digoxin's Effects on the Cardiac Action Potential

Digoxin does not directly affect a specific phase of the cardiac action potential through ion channel blockade; instead, it works indirectly by inhibiting the sodium-potassium ATPase pump, which leads to increased intracellular calcium and produces vagomimetic effects that primarily influence Phase 4 (diastolic depolarization) and AV nodal conduction. 1, 2

Mechanism of Action

Digoxin's primary cellular target is the sodium-potassium ATPase enzyme, not a specific action potential phase 1, 2. This inhibition creates a cascade of effects:

• Increased intracellular sodium → leads to increased intracellular calcium via sodium-calcium exchange
• Enhanced calcium availability → positive inotropic effect (increased contractility)
• Vagomimetic (parasympathetic) effects → slows SA and AV nodal conduction 1

Effects on Action Potential Characteristics

At Therapeutic Doses (Low Serum Concentrations)

Phase 4 and AV Nodal Effects:

• Vagomimetic effects decrease sinus and AV nodal conduction 1
• Increases baroreceptor sensitivity disproportionate to hemodynamic improvement 1
• Slows heart rate through enhanced parasympathetic tone 2

Atrial Tissue Effects:

• Shortens atrial action potential duration (AAPD) and effective refractory period (AERP) 3
• Depolarizes atrial resting membrane potential 3
• Slows intra-atrial conduction 3
• Produces non-uniform shortening of AAPD and AERP, likely by activating IKACh (acetylcholine-activated potassium current) 3

At Higher Serum Concentrations (Toxic Range)

Paradoxical effects emerge:

• Parasympathetic effects shorten the refractory period of non-nodal specialized conduction tissue 1
• Increases sympathetic outflow from the CNS, which may be an important factor in digitalis toxicity 2
• Can cause oscillation of adsorbed ions on cell surface and incomplete channel structure, leading to cardiac ectopic beats 4

Biphasic Action Potential Duration Effects

Research demonstrates a biphasic effect on action potential duration 5:

• Initial phase (within 10 minutes): Action potential duration lengthens
• Later phase (after 10 minutes): Action potential duration shortens
• This biphasic effect is related to extracellular potassium concentration 5

Clinical Implications

Important Caveats:

1. Digoxin is NOT a direct ion channel blocker like calcium channel blockers (which affect Phase 2) or beta-blockers (which affect Phase 4 slope). Its effects are mediated through pump inhibition and autonomic modulation 1, 2

2. Time-dependent effects matter: Peak serum concentrations occur 1-3 hours after oral administration, but the peak pharmacologic effect occurs 2-6 hours post-dose due to tissue distribution 2

3. Toxicity can occur at therapeutic levels: Clinical features trump serum concentrations in diagnosing toxicity 6, 7. The traditionally accepted therapeutic range (0.8-2.0 ng/mL) has been reassessed, with increased mortality observed at levels >1.0 ng/mL 8

4. Proarrhythmic effects are not time-dependent: Recent evidence shows ventricular ectopic burden does not correlate with peak versus trough drug levels, suggesting toxicity risk is not driven by intra-day fluctuations 9

Contraindications Related to Action Potential Effects:

• Accessory pathways (WPW syndrome): Digoxin's shortening of atrial refractory period can facilitate anterograde conduction through the accessory pathway, potentially causing ventricular fibrillation 1, 10

• Obstructive hypertrophic cardiomyopathy: Should be avoided 1